Table 3 Baseline characteristics of inpatients with MDR and susceptible infection or colonisation before and after PSM
From: Economic burden of antibiotic resistance in China: a national level estimate for inpatients
Baseline characteristics | Before PSM | After PSM | ||||
|---|---|---|---|---|---|---|
Susceptible | MDR | P-value | Susceptible | MDR | P-value | |
Number of inpatients, n | 3163 | 7368 | 3048 | 3048 | ||
Age in year, median (Min–Max) | 68 (0–100) | 72 (0–102) | < 0.000 | 68 (0–100) | 70 (1–100) | 0.955 |
Sex male, n (%) | 1904 (60.2) | 4168 (56.6) | 0.001 | 1805 (59.2) | 1815 (59.6) | 0.794 |
Insurance, n (%) | 2529 (80.0) | 6122 (83.1) | < 0.000 | 2469 (81.0) | 2424 (79.5) | 0.148 |
Number of diagnosis, median (Min–Max) | 6 (1–36) | 6 (1–37) | < 0.000 | 6 (1–36) | 6 (1–37) | 0.945 |
CCI, median (Min–Max) | 5 (1–37) | 5 (1–39) | < 0.000 | 5 (1–37) | 5 (1–28) | 0.626 |
Admission to ICU, n (%) | 335 (10.6) | 1133 (15.4) | < 0.000 | 333 (10.9) | 356 (11.7) | 0.352 |
Surgery, n (%) | 923 (29.2) | 2239 (30.4) | 0.215 | 899 (29.5) | 965 (31.7) | 0.067 |
Myocardial infraction, n (%) | 92 (2.9) | 197 (2.7) | 0.499 | 87 (2.9) | 95 (3.1) | 0.547 |
Congestive heart failure, n (%) | 620 (19.6) | 1193 (16.2) | < 0.000 | 577 (18.9) | 569 (18.7) | 0.793 |
Peripheral vascular disease, n (%) | 45 (1.4) | 93 (1.3) | 0.507 | 43 (1.4) | 48 (1.6) | 0.597 |
Cerebrovascular diseases, n (%) | 1428 (45.2) | 3444 (46.7) | 0.132 | 1392 (45.7) | 1410 (46.3) | 0.644 |
Dementia, n (%) | 45 (1.4) | 277 (3.8) | < 0.000 | 45 (1.5) | 45 (1.5) | 1.000 |
Chronic pulmonary disease, n (%) | 969 (30.6) | 1451 (19.7) | < 0.000 | 867 (28.4) | 894 (29.3) | 0.445 |
Connective tissue disease, n (%) | 80 (2.5) | 189 (2.6) | 0.915 | 80 (2.6) | 96 (3.2) | 0.221 |
Mild liver disease, n (%) | 109 (3.5) | 321 (4.4) | 0.030 | 109 (3.6) | 104 (3.4) | 0.727 |
Peptic ulcer disease, n (%) | 69 (2.2) | 199 (2.7) | 0.121 | 68 (2.2) | 71 (2.3) | 0.797 |
Diabetes mellitus, n (%) | 795 (25.1) | 2137 (29.0) | < 0.000 | 791 (26.0) | 775 (25.4) | 0.639 |
Diabetes mellitus with chronic complication, n (%) | 112 (3.5) | 293 (4.0) | 0.286 | 112 (3.7) | 108 (3.5) | 0.784 |
Moderate to severe chronic kidney disease, n (%) | 212 (6.7) | 713 (9.68) | < 0.000 | 212 (7.0) | 194 (6.4) | 0.355 |
Hemiplegia, n (%) | 20 (0.6) | 101 (1.4) | 0.001 | 20 (0.7) | 17 (0.6) | 0.621 |
Solid tumor without metastases, n (%) | 223 (7.1) | 729 (9.9) | < 0.000 | 223 (7.3) | 216 (7.1) | 0.729 |
Leukemia, n (%) | 37 (1.2) | 130 (1.8) | 0.025 | 37 (1.2) | 39 (1.3) | 0.817 |
Malignant lymphoma, n (%) | 24 (0.8) | 85 (1.2) | 0.066 | 24 (0.8) | 22 (0.7) | 0.767 |
Severe liver disease, n (%) | 34 (1.1) | 109 (1.5) | 0.100 | 34 (1.1) | 30 (1.0) | 0.615 |
Metastasis tumor, n (%) | 137 (4.3) | 316 (4.3) | 0.921 | 136 (4.5) | 142 (4.7) | 0.713 |